BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
June 03, 2026 21:55 ET | Source: BrightSpring Health Services, Inc. LOUISVILLE,…
POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding
Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1…
ACTG Launches HIV Cure Study Evaluating Novel Approach Targeting the HIV Reservoir
CHAPEL HILL, N.C., June 03, 2026 (GLOBE NEWSWIRE) -- ACTG, a global…
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogrens Disease at EULAR 2026
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and…
JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)
Favorable safety and tolerability profile, with rapid onset of clinical activity and…
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied…
Philips announces exchange ratio for 2025 dividend
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the…
FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
Exceptional track record across multiple clinical development programs for depression, three of…
Nanobiotix Joins the Euronext Tech Leaders Index
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext:…
